866-997-4948(US-Canada Toll Free)

Nasal Polyps (Nasal Polyposis) - Pipeline Review, H1 2019

Published By :

Global Markets Direct

Published Date : Mar 2019

Category :

Pharmaceutical

No. of Pages : 96 Pages

Nasal Polyps (Nasal Polyposis) - Pipeline Review, H1 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Nasal Polyps (Nasal Polyposis) - Pipeline Review, H1 2019, provides an overview of the Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) pipeline landscape.

Nasal polyps (Nasal polyposis) is an inflammatory condition develops in the nasal lining of nose. They are non-cancerous growths. Signs and symptoms include runny nose, postnasal drip, headache, snoring and loss of sense of taste. Risk factors include asthma, aspirin sensitivity, cystic fibrosis, Churg-strauss syndrome and allergic fungal sinusitis. Treatment includes steroid medications.

Nasal Polyps (Nasal Polyposis) - Therapeutics DevelopmentPipeline Overview Number of Products under Development for Nasal Polyps (Nasal Polyposis), H1 2019

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Nasal Polyps (Nasal Polyposis) - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Nasal Polyps (Nasal Polyposis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Unknown stages are 1, 3, 3, 2 and 1 respectively.

Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders).
- The pipeline guide reviews pipeline therapeutics for Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Introduction
Nasal Polyps (Nasal Polyposis) - Overview
Nasal Polyps (Nasal Polyposis) - Therapeutics Development
Nasal Polyps (Nasal Polyposis) - Therapeutics Assessment
Nasal Polyps (Nasal Polyposis) - Companies Involved in Therapeutics Development
Nasal Polyps (Nasal Polyposis) - Drug Profiles
Nasal Polyps (Nasal Polyposis) - Dormant Projects
Nasal Polyps (Nasal Polyposis) - Discontinued Products
Nasal Polyps (Nasal Polyposis) - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Nasal Polyps (Nasal Polyposis), H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Number of Products by Stage and Target, H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Nasal Polyps (Nasal Polyposis) - Pipeline by AnaptysBio Inc, H1 2019
Nasal Polyps (Nasal Polyposis) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2019
Nasal Polyps (Nasal Polyposis) - Pipeline by GlaxoSmithKline Plc, H1 2019
Nasal Polyps (Nasal Polyposis) - Pipeline by Idorsia Pharmaceutical Ltd, H1 2019
Nasal Polyps (Nasal Polyposis) - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2019
Nasal Polyps (Nasal Polyposis) - Pipeline by Novartis AG, H1 2019
Nasal Polyps (Nasal Polyposis) - Pipeline by OptiNose US Inc, H1 2019
Nasal Polyps (Nasal Polyposis) - Pipeline by Pfizer Inc, H1 2019
Nasal Polyps (Nasal Polyposis) - Pipeline by Regeneron Pharmaceuticals Inc, H1 2019
Nasal Polyps (Nasal Polyposis) - Pipeline by Suzhou Connect Biopharmaceuticals Ltd, H1 2019
Nasal Polyps (Nasal Polyposis) - Dormant Projects, H1 2019
Nasal Polyps (Nasal Polyposis) - Discontinued Products, H1 2019

List of Figures
Number of Products under Development for Nasal Polyps (Nasal Polyposis), H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products by Targets, H1 2019
Number of Products by Stage and Targets, H1 2019
Number of Products by Mechanism of Actions, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Top 10 Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *